Research Synthesis: Hormone Optimization

Abstract

This paper synthesizes hormone optimization hrt as an aging-related intervention across 22 included source papers and 994 high-confidence extracted claims.

The evidence profile contains no sources classified primarily as direct clinical evidence, 15 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 83 cross-study disagreements across the evidence base.

Positive study-level signals are summarized in the cardiometabolic and contextual adjacent evidence outcome classes, null signals in the contextual adjacent evidence, skeletal, fracture, and bone and safety and comorbidity outcome classes, and negative signals in the longevity outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that hormone optimization hrt should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

Methods

Review type and protocol

This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-hormone_optimization_hrt-v06-DAILY-2026-06-01T17-57-53Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-01.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• hormone replacement therapy AND aging AND mortality
• testosterone therapy AND older men AND muscle
• menopause hormone therapy AND cardiovascular outcomes
• DHEA AND aging AND randomized trial
• growth hormone secretagogue AND older adults

Eligibility criteria

• Sources whose primary content addresses hormone optimization hrt.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 153 records in the receipt-candidate union, 33 were classified as source candidates and 22 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	153
Classified source candidates	33
No extractable claims	43
None-only claim binding	14
Mixed partial-or-none claim-binding candidates	39
Partial-only claim-binding candidates	21
Strict high-confidence sources	3
Admitted final sources	22

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, longevity, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Outcome class	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=13; claims=745	no extracted directional signal in 10/13 sources	11 indirect; 2 review	limited corpus depth in this outcome class
Cardiometabolic	n=4; claims=175	unclear signal in 2/4 sources	1 indirect; 3 review	limited corpus depth in this outcome class
Skeletal, Fracture, and Bone	n=3; claims=57	no extracted directional signal in 3/3 sources	2 indirect; 1 review	limited corpus depth in this outcome class
Longevity	n=1; claims=7	negative signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Safety and Comorbidity	n=1; claims=10	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Contextual Adjacent Evidence Outcomes

13 included sources were assigned to this outcome class. Directional coding: null=10, positive=1, unclear=2. Directness coding: indirect=11, review=2.

Cardiometabolic Outcomes

Cardiometabolic remains a separate Results slice (n=4; claims=175; unclear signal in 2/4 sources; 1 indirect; 3 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes.

Skeletal Fracture Bone Outcomes

3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=2, review=1.

Longevity Outcomes

1 included source were assigned to this outcome class. Directional coding: negative=1. Directness coding: review=1.

Safety Comorbidity Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus is dominated by observational cohort designs; no large, long-duration randomized controlled trial evaluating hard cardiovascular events, cancer incidence, or all-cause mortality with hormone replacement therapy is represented. For example, the Women's Health Initiative, the single most influential HRT RCT, is absent from the included source set, as are the HERS trials and WHI-Confirmatory. This gap means the synthesis cannot adjudicate the effect of HRT on major adverse cardiovascular events or total mortality from first principles within this corpus; it must instead rely on secondary reviews (Gu 2024) that themselves aggregate external trial data. Consequently, headline safety conclusions remain externally derived rather than corpus-grounded.

Several clinically important outcome classes are touched by only a single source, precluding internal replication. Bone mineral density changes with growth hormone replacement therapy, for instance, are supported solely by the Xue 2013 meta-analysis; no second corpus study examines that endpoint, so the direction and magnitude cannot be independently verified within this evidence set. Single-source findings carry inherent fragility because a methodological error or population-specific confound cannot be detected through cross-study comparison.

Population specificity limits external validity across several dimensions. The corpus includes specialised subgroups — girls with Turner syndrome (Segerer 2020), gynecological cancer survivors undergoing surgical menopause (Karakida 2025, Villa 2024, Naglic 2024), transgender individuals seeking hormone therapy (Venugopal 2025), and APOE4 carrier women (Saleh 2023) — whose treatment effects may not generalise to the broader peri- and postmenopausal population. Several sources enrolled exclusively or predominantly White European or East Asian cohorts, and race- or ethnicity-specific pharmacokinetic differences in estrogen metabolism are not represented.

Critical endpoints remain unmeasured within this corpus. No source reports prospective data on HRT-related cancer incidence (breast, endometrial, or ovarian) as a primary outcome, despite this being one of the most debated risks in the clinical literature. Quality-of-life outcomes are mentioned anecdotally (Karakida 2025; Villa 2024) but are not systematically captured with validated instruments across multiple studies, nor is patient-reported vasomotor symptom burden quantitatively pooled. Long-term fracture incidence under HRT is referenced only through a single BMD meta-analysis (Xue 2013) using the surrogate endpoint of bone density rather than actual fracture events (Ioannidis 2005). Finally, the mechanism-to-clinic gap is substantial: several reviews (Srensen 2001, Blackburn 2026) articulate plausible biological pathways linking sex hormones to cardiometabolic and body-composition improvements, but the absence of parallel hard-outcome RCT evidence means mechanistic plausibility cannot be translated into a clinical recommendation within the boundaries of this evidence set.

Conclusion

For hormone optimization hrt, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support hormone optimization hrt as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 22 included sources on Hormone optimization across 5 outcome classes and 83 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 22 curated reference papers, the evidence base for Hormone optimization shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Negative signals appear in: longevity. Null findings dominate: contextual other, skeletal fracture bone. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Hormone optimization anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the null vs positive between Srensen 2001 and Venugopal 2025 on cardiometabolic (severity 3/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (E 2026, Srensen 2001, Improving 2026) emphasize convergent signals on Hormone optimization. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Outcome class	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
cardiometabolic	0	4	null, positive, unclear	direct clinical gap
longevity	0	1	negative	direct clinical gap
contextual adjacent evidence	0	13	null, positive, unclear	direct clinical gap
safety and comorbidity	0	1	null	direct clinical gap
skeletal, fracture, and bone	0	3	null	direct clinical gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	cardiometabolic: direct clinical gap	0 direct and 4 indirect sources; direction profile: null, positive, unclear
P2	longevity: direct clinical gap	0 direct and 1 indirect source; direction profile: negative
P3	contextual adjacent evidence: direct clinical gap	0 direct and 13 indirect sources; direction profile: null, positive, unclear
P4	safety and comorbidity: direct clinical gap	0 direct and 1 indirect source; direction profile: null
P5	skeletal, fracture, and bone: direct clinical gap	0 direct and 3 indirect sources; direction profile: null

Next-Study Design Recommendation

The next high-yield study for Hormone optimization should target the cardiometabolic evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• E 2026; Review / meta-analysis; tier=B1; directness=review; N=—; population=adults; endpoint=longevity; direction=negative; representative statistic=P = 0.039.
• Srensen 2001; Review / meta-analysis; tier=B1; directness=review; N=—; population=frail / sarcopenic adults; endpoint=cardiometabolic; direction=unclear.
• Improving 2026; Review / meta-analysis; tier=B1; directness=review; N=—; population=adults; endpoint=cardiometabolic; direction=unclear.
• Saleh 2023; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=null; representative statistic=P = 0.002.
• Gu 2024; Observational; tier=B2; directness=review; N=—; population=—; endpoint=cardiometabolic; direction=positive; representative statistic=P = 0.0003.
• Abdalla 2026; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=unclear; representative statistic=P = 0.18.
• Villa 2024; Observational; tier=B2; directness=review; N=—; population=—; endpoint=contextual other; direction=null; representative statistic=p ≤ 0.05.
• Segerer 2020; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=positive; representative statistic=P = 0.003.
• CHUNG 2025; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=null; representative statistic=P < 0.001.
• Hao 2024; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=null; representative statistic=P < 0.001.

Load-Bearing Tensions

• Severity 3 null vs positive: Improving 2026 vs Venugopal 2025; Improving 2026 (unclear) vs Venugopal 2025 (null) on cardiometabolic
• Severity 3 null vs positive: Gu 2024 vs Venugopal 2025; Gu 2024 (positive) vs Venugopal 2025 (null) on cardiometabolic
• Severity 3 null vs positive: Villa 2024 vs Abdalla 2026; Villa 2024 (null) vs Abdalla 2026 (unclear) on contextual other
• Severity 3 null vs positive: Villa 2024 vs Blackburn 2026; Villa 2024 (null) vs Blackburn 2026 (unclear) on contextual other
• Severity 3 null vs positive: Villa 2024 vs Segerer 2020; Villa 2024 (null) vs Segerer 2020 (positive) on contextual other
• Severity 3 null vs positive: Andy 2024 vs Abdalla 2026; Andy 2024 (null) vs Abdalla 2026 (unclear) on contextual other
• Severity 3 null vs positive: Andy 2024 vs Blackburn 2026; Andy 2024 (null) vs Blackburn 2026 (unclear) on contextual other

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: McCartney 2025, Hackett 2024, Fujio 2024, Costris 2025, Vijay 2025, Murta 2025, WHO 2000.

References

• Saleh 2023. Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer’s Disease (EPAD) cohort. Alzheimer's Research & Therapy, 2023. DOI: 10.1186/s13195-022-01121-5. PMID: 36624497.
• Gu 2024. The benefits and risks of menopause hormone therapy for the cardiovascular system in postmenopausal women: a systematic review and meta-analysis. BMC Women's Health, 2024. DOI: 10.1186/s12905-023-02788-0. PMID: 38263123.
• Abdalla 2026. Histological signatures of hormone replacement therapy in the endometrium. Frontiers in Medicine, 2026. DOI: 10.3389/fmed.2026.1718508. PMID: 41907294.
• Villa 2024. Hormone Replacement Therapy in Post-Menopause Hormone-Dependent Gynecological Cancer Patients: A Narrative Review. Journal of Clinical Medicine, 2024. DOI: 10.3390/jcm13051443. PMID: 38592285.
• Segerer 2020. Increased Insulin Concentrations During Growth Hormone Treatment in Girls With Turner Syndrome Are Ameliorated by Hormone Replacement Therapy. Frontiers in Endocrinology, 2020. DOI: 10.3389/fendo.2020.586055. PMID: 33381083.
• CHUNG 2025. Patient-reported Impact of Menopause and Hormone Replacement Therapy on Psoriasis. Acta Dermato-Venereologica, 2025. DOI: 10.2340/actadv.v105.42843. PMID: 40205797.
• Hao 2024. The effect of gonadotropin-releasing hormone agonist downregulation in conjunction with hormone replacement therapy on endometrial preparation in patients for frozen–thawed embryo transfer. Frontiers in Medicine, 2024. DOI: 10.3389/fmed.2024.1412126. PMID: 39021824.
• McCartney 2025. Does online information about hormone replacement therapy (or menopause hormone therapy) reflect indications from the British National Formulary and guidance from the National Institute for Health and Care Excellence: a cross-sectional study of UK media. BMJ Open, 2025. DOI: 10.1136/bmjopen-2024-094773. PMID: 40908004.
• Xue 2013. Effects of Growth Hormone Replacement Therapy on Bone Mineral Density in Growth Hormone Deficient Adults: A Meta-Analysis. International Journal of Endocrinology, 2013. DOI: 10.1155/2013/216107. PMID: 23690770.
• Karakida 2025. Changes in Quality of Life, Depression, and Menopausal Symptoms After Surgical Menopause and the Efficacy of Hormone Replacement Therapy in Gynecological Cancer Survivors: A One-Year Prospective Longitudinal Study. Medicina, 2025. DOI: 10.3390/medicina61071191. PMID: 40731820.
• Andy 2024. Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition. Frontiers in Endocrinology, 2024. DOI: 10.3389/fendo.2024.1350318. PMID: 38501109.
• Naglic 2024. Hormone replacement therapy in surgical menopause after gynecological malignancies. Biomolecules and Biomedicine, 2024. DOI: 10.17305/bb.2024.11220. PMID: 39556012.
• Hackett 2024. Long Term Cardiovascular Safety of Testosterone Therapy: A Review of the TRAVERSE Study. The World Journal of Men's Health, 2024. DOI: 10.5534/wjmh.240081. PMID: 39344109.
• E 2026. Abstract PS3-01-26: Estrogen hormone replacement therapy (E-HRT) and Tamoxifen: Prevention versus Adjuvant setting. Clinical Cancer Research, 2026. DOI: 10.1158/1557-3265.sabcs25-ps3-01-26.
• Venugopal 2025. SUN-142 Preferences and Barriers to Hormone Replacement Therapy in the Transgender Population-Single Center Experience. Journal of the Endocrine Society, 2025. DOI: 10.1210/jendso/bvaf149.2075.
• Fujio 2024. 6731 Initial therapeutic effects of weekly growth hormone replacement therapy: somapacitan. Journal of the Endocrine Society, 2024. DOI: 10.1210/jendso/bvae163.1249.
• Costris 2025. SAT-783 83y Old Woman On Long-Term Hormone Replacement Therapy (HRT) for Osteoporosis (OP) Management: n of 1, Revisiting the Role of HRT in OP Management. Journal of the Endocrine Society, 2025. DOI: 10.1210/jendso/bvaf149.636.
• Vijay 2025. SAT-104 Pituitary Hormone Replacement Therapy in the First Year After Diagnosis of Pediatric Craniopharyngioma. Journal of the Endocrine Society, 2025. DOI: 10.1210/jendso/bvaf149.1586.
• Srensen 2001. Obesity and Sarcopenia after Menopause Are Reversed by Sex Hormone Replacement Therapy. Obes Res, 2001. DOI: 10.1038/oby.2001.81. PMID: 11595778.
• Murta 2025. MON-196 Hormone Replacement Therapy In Menopausal Patient With Symptomatic Endometriosis And Bone Metabolism: A Case Report. Journal of the Endocrine Society, 2025. DOI: 10.1210/jendso/bvaf149.1927.
• Blackburn 2026. Hormone replacement therapy and cardiovascular risk in postmenopausal women. European Heart Journal Open, 2026. DOI: 10.1093/ehjopen/oeag054. PMID: 42027787.
• Improving 2026. Improving detection and treatment of psychological distress during menopause: evidence from a clinical hormone replacement therapy cohort. BJPsych International, 2026. DOI: 10.1192/bji.2025.10094.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• WHO 2000. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. 2000. PMID: 11234459.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.